Nuvectis Pharma insider purchase: 5,000 shares; stake 3.53M

Rhea-AI Filing Summary

Nuvectis Pharma (NVCT) reported an insider purchase by Chairman & CEO Ron Bentsur. On 11/05/2025, he bought 5,000 shares of common stock at $5.72 per share (transaction code P). Following the trade, his directly held beneficial ownership totals 3,525,924 shares.

The total includes 676,759 shares of restricted stock, as noted in the footnote. Bentsur is listed as Director, Chairman & CEO, and a 10% Owner, with the reported holdings shown as Direct (D).

Insider Trade Summary

Net Buyer: 5,000 shares ($28,600)

Net Buy 1 txn

Insider BENTSUR RON

Role Chairman & CEO

Bought 5,000 shs ($29K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$5.72	$29K

Holdings After Transaction: Common Stock — 3,525,924 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENTSUR RON

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NJ 07024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2025		P		5,000	A	$5.72	3,525,924(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 676,759 shares of restricted stock.

	/s/ Ron Bentsur	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NVCT disclose on Form 4?

Ron Bentsur purchased 5,000 shares of Nuvectis Pharma common stock at $5.72 on 11/05/2025.

What is Ron Bentsur’s total beneficial ownership after the NVCT trade?

He directly holds 3,525,924 shares after the reported transaction.

Does the NVCT ownership total include restricted stock?

Yes. It includes 676,759 shares of restricted stock.

What roles does the reporting person hold at NVCT?

He is a Director, Chairman & CEO, and a 10% Owner.

What was the transaction code for the NVCT insider trade?

The code was P, indicating an open-market or private purchase.

Is the NVCT ownership reported as direct or indirect?

The filing lists ownership as Direct (D).

When was the Form 4 signed?

The signature date shown is 11/06/2025.